Skip to main content

Alnylam and Mayo Clinic Partner to Develop RNAi Parkinson s Drug

NEW YORK, Oct. 30 - Alnylam, of Cambridge, Mass., has formed a collaboration with researchers at the Mayo Clinic in Rochester, Minn., to develop an RNA interference-based drug that suppresses genes over-expressed in people with Parkinson's disease, the company said today.

 

Under the collaboration, Alnylam will define and synthesize RNA interference -  or RNAi -- compounds, and will provide them to the Mayo Clinic researchers, which have recently identified a causal pathway in Parkinson's disease and published these findings in Science.  Alnylam will also fund research at the Mayo Clinic for development of the drug that expresses a gene in the pathway, alpha-synuclein, the company said. The Mayo Clinic researchers will test the RNAi compounds and test them for in vitro and in vivo efficacy.

 

"This collaboration with Alnylam creates the possibility of previously unimagined therapeutic advances for Parkinson's patients," Matthew Farrer, assistant professor of neuroscience and the director of a neurogenetics laboratory at Mayo Clinic in Jacksonville, Fla., said in a statement.

 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.